Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Steinberg

Showing results (981-990 of 1,520) with videos related to

Pageof 152
Sort By:
Cancer|January 22, 2010
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancerGisele A Sarosy, Mahrukh M Hussain, Michael V Seiden, et al.
Molecular and Cellular Biology|April 10, 2002
RAG-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient miceLisa K Petiniot, Zoë Weaver, Melanie Vacchio, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 1989
Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failureJ L Bader, M E Horowitz, R Dewan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 21, 2007
Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counselingJean Jenkins, Kathleen A Calzone, Eileen Dimond, et al.
Leukemia & Lymphoma|February 3, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomasRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Oncogene|January 1, 1992
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical featuresT Mitsudomi, S M Steinberg, M M Nau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV InfectionRamya Ramaswami, Mark N Polizzotto, Kathryn Lurain, et al.
Urologic Oncology|June 18, 2021
Clinical value of <sup>18</sup>FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancerAli Cahid Civelek, Scot A Niglio, Ashkan A Malayeri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancerO S Breathnach, M S Georgiadis, B S Schuler, et al.
The Journal of Laboratory and Clinical Medicine|March 2, 2002
Effects of interleukin 2 therapy on lymphocyte magnesium levelsMark D McKee, Stacey A Cecco, Julie E Niemela, et al.
Pageof 152

Showing results (981-990 of 1,520) with videos related to

Sort By:
Pageof 152
Cancer|January 22, 2010
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancerGisele A Sarosy, Mahrukh M Hussain, Michael V Seiden, et al.
Molecular and Cellular Biology|April 10, 2002
RAG-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient miceLisa K Petiniot, Zoë Weaver, Melanie Vacchio, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 1989
Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failureJ L Bader, M E Horowitz, R Dewan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 21, 2007
Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counselingJean Jenkins, Kathleen A Calzone, Eileen Dimond, et al.
Leukemia & Lymphoma|February 3, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomasRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Oncogene|January 1, 1992
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical featuresT Mitsudomi, S M Steinberg, M M Nau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV InfectionRamya Ramaswami, Mark N Polizzotto, Kathryn Lurain, et al.
Urologic Oncology|June 18, 2021
Clinical value of <sup>18</sup>FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancerAli Cahid Civelek, Scot A Niglio, Ashkan A Malayeri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancerO S Breathnach, M S Georgiadis, B S Schuler, et al.
The Journal of Laboratory and Clinical Medicine|March 2, 2002
Effects of interleukin 2 therapy on lymphocyte magnesium levelsMark D McKee, Stacey A Cecco, Julie E Niemela, et al.
Pageof 152